Literature DB >> 25517610

Balance and imbalance in the immune system: life on the edge.

Suzanne L Topalian1, Arlene H Sharpe2.   

Abstract

CTLA-4 is a key immune checkpoint in maintaining self-tolerance, which can be co-opted by cancer to evade immune attack. In Science, Kuehn et al. (2014) describe clinical manifestations from inherited heterozygous CTLA4 mutations, and some are reminiscent of immune-related consequences from anti-CTLA-4 cancer therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25517610      PMCID： PMC4710093          DOI： 10.1016/j.immuni.2014.11.005

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  10 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease.

Authors:  Lawrence Steinman
Journal:  Eur J Immunol       Date:  2014-11       Impact factor: 5.532

3.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

Authors:  Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha M Quezado; James C Yang; Richard M Sherry; Suzanne L Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoff Nichol; Michael J Yellin; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

4.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

5.  CTLA-4 control over Foxp3+ regulatory T cell function.

Authors:  Kajsa Wing; Yasushi Onishi; Paz Prieto-Martin; Tomoyuki Yamaguchi; Makoto Miyara; Zoltan Fehervari; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2008-10-10       Impact factor: 47.728

6.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

7.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

8.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

9.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Authors:  Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi
Journal:  Nat Med       Date:  2014-10-20       Impact factor: 53.440

10.  Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.

Authors:  Kok-Fai Kong; Guo Fu; Yaoyang Zhang; Tadashi Yokosuka; Javier Casas; Ann J Canonigo-Balancio; Stephane Becart; Gisen Kim; John R Yates; Mitchell Kronenberg; Takashi Saito; Nicholas R J Gascoigne; Amnon Altman
Journal:  Nat Immunol       Date:  2014-04-06       Impact factor: 25.606
  10 in total
  12 in total

Review 1.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

2.  Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

Authors:  James Larkin; Bartosz Chmielowski; Christopher D Lao; F Stephen Hodi; William Sharfman; Jeffrey Weber; Karijn P M Suijkerbuijk; Sergio Azevedo; Hewei Li; Daniel Reshef; Alexandre Avila; David A Reardon
Journal:  Oncologist       Date:  2017-05-11

Review 3.  How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation.

Authors:  Roshini S Abraham
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 4.  Introduction to immunotherapy for brain tumor patients: challenges and future perspectives.

Authors:  Megan L Montoya; Noriyuki Kasahara; Hideho Okada
Journal:  Neurooncol Pract       Date:  2020-03-09

5.  Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.

Authors:  Henoch S Hong; Sven D Koch; Birgit Scheel; Ulrike Gnad-Vogt; Andreas Schröder; Karl-Josef Kallen; Volker Wiegand; Linus Backert; Oliver Kohlbacher; Ingmar Hoerr; Mariola Fotin-Mleczek; James M Billingsley
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

6.  Immunotherapy for Metastatic Melanoma with Right Atrial Involvement in a Patient with Rheumatoid Arthritis.

Authors:  Zachary Benson; Sarah Gordon; Patricia Nicolato; Andrew Poklepovic
Journal:  Case Rep Oncol Med       Date:  2017-12-28

Review 7.  Immune Checkpoint in Glioblastoma: Promising and Challenging.

Authors:  Jing Huang; Fangkun Liu; Zhixiong Liu; Hui Tang; Haishan Wu; Qianni Gong; Jindong Chen
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

8.  Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells.

Authors:  Xiu-Man Zhou; Wan-Qiong Li; Ya-Hong Wu; Lu Han; Xin-Guang Cao; Xuan-Ming Yang; Hong-Fei Wang; Wen-Shan Zhao; Wen-Jie Zhai; Yuan-Ming Qi; Yan-Feng Gao
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

9.  Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors.

Authors:  Despina Michailidou; Ali Raza Khaki; Maria Pia Morelli; Leonidas Diamantopoulos; Namrata Singh; Petros Grivas
Journal:  Sci Rep       Date:  2021-04-27       Impact factor: 4.379

10.  Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.

Authors:  Jong Shin; Paul J Phelan; Ole Gjoerup; William Bachovchin; Peter A Bullock
Journal:  Protein Expr Purif       Date:  2020-09-25       Impact factor: 1.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.